Hansa Biopharma: Imlifidase records a very healthy improvement during Q4 after a quarter with low activity - Redeye

Hansa delivers a positive surprise in Q4 as Idefirix records European product sales of SEK 43m in Q4, which compares with our expected SEK 23m and SEK 16m in Q3. In Q4, Hansa experienced support from countries like the UK, Spain and Germany. The increased early Q4 product sales support is also positive, as Idefirix will secure additional sales related to the Eurotransplant program during 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/969477/hansa-biopharma-preliminary-q4-imlifidase-records-a-very-healthy-improvement-during-q4-after-a-quarter-with-low-activity?utm_source=finwire&utm_medium=RSS